Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture.Manufacturer Supply with High Purity and Stable Quality Chemical Name: Moc-L-Tert-Leucine CAS: 162537-11-3 Intermediate of Atazanavir HIV-1 Protease Inhibitor High Quality, Commercial Production| Item | Specifications |
| Appearance | White to Off-White Crystals |
| Identification Methods | HPLC |
| Purity/Analysis Method | ≥99.0% (HPLC) |
| Moc-L-Tle-Tle-OH | ≤0.30% |
| L-Moc-Dimer | ≤0.30% |
| L-Tle-OH | ≤0.10% |
| Methoxycarbonyl-L-Valine | ≤0.10% |
| N-Acetyl-L-tert-Leucine | ≤0.05% |
| Individual Unkown Impurity | ≤0.30% |
| Total Impurities | ≤1.0% |
| Enantiomer Content | ≤0.10% (By Chiral HPLC) |
| Water Content | ≤0.50% (By K.F) |
| Loss on Drying | ≤0.50% |
| Residue on Ignition | ≤0.20% |
| Heavy Metals | ≤10ppm |
| Usage | Amino Acid; Intermediate of Atazanavir (CAS 198904-31-3) |
Description:
Specifications:
Package & Storage:
| Chemical Name | Moc-L-Tert-Leucine |
| Synonyms | Methoxycarbonyl-L-tert-Leucine; N-(Methoxycarbonyl)-tert-Leucine; Atazanavir Related Compound A |
| CAS Number | 162537-11-3 |
| CAT Number | RF-PI289 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C8H15NO4 |
| Molecular Weight | 189.21 |
| Melting Point | 109℃ |
| Density | 1.126 g/cm3 |
| Boiling Point | 320.9℃ at 760 mmHg |
| Solubility | Soluble in Ethyl Acetate and Methanol |
| Shipping Condition | Shipped Under Ambient Temperature |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of Moc-L-Tert-Leucine (CAS 162537-11-3) with high quality. Moc-L-Tert-Leucine is a kind of amino acid deriviative. It is a very useful intermediate for efficient synthesis of the HIV protease inhibitor Atazanavir (CAS 198904-31-3) as well as Atazanavir sulfate (CAS 229975-97-7). Atazanavir is an antiretroviral agent that has been approvedby the FDA for use in combination with other anti-RTagents for the treatment of HIV infections. The drug is always used in combination with RT inhibitors. Atazanavir is an inhibitor of HIV-1 protease (EC50=2.6 nM). In isolated cells, it has additive to moderately synergistic antiviral effects when combined with other antiretroviral drugs. As a result, it is commonly used in vivo in combination therapy for HIV-1 infection.
